Benlysta® is the first medicine specifically developed and approved for lupus and the first lupus therapy approved for lupus nephritis. It was developed by Human Genome Sciences (HGS) in partnership ...

GlaxoSmithKline is buying Human Genome Sciences for $3.6 billion, giving it full ownership of Benlysta, along with albiglutide and darapladib, after months of M&A intrigue. “We are pleased to have ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8e8871/product_profiles) has announced the addition of the "Product Profiles ...

Benlysta, GlaxoSmithKline's treatment for autoimmune disease lupus has been recommended by NICE, after the company agreed to a price cut and a real world data study. The decision comes after years of ...

Analysts have been reflecting on the US approval granted to Human Genome Sciences and GlaxoSmithKline's lupus drug Benlysta and what it means for patients and the two companies. Analysts have been ...

Rockville, Maryland (USA) and Basel, Switzerland - 13 July 2010 - Human Genome Sciences, Inc. (Nasdaq: HGSI) and Lonza today announced an agreement for the future commercial supply of BENLYSTA® ...

-- Accelerated Royalty Payments to Support Ongoing R&D and Commercial Investments as Biogen Idec Prepares for Multiple Potential Product Launches in Coming Years -- (NASDAQ: BIIB) and DRI Capital ...